E14111 Background: In 2015, The FDA approved the most number of novel drugs in the last 19-years. We propose to evaluate the factors associated with the significant increase in FDA approved oncologic drugs over the last 5 years. Methods: Data was extracted from all novel drug license applications to the FDA. SAS was used to conduct Chi-squared tests. Results: The FDA approved 47 novel cancer drugs from 2011 to 2015, of which, 34 (72.3%) were new drug applications and 13 (27.7%) were biologic license applications. Of these, 35 (64.5%) were orphan and 19 (40.4%) were first-in-class drugs. Based on expedited approval, 36 (76.6%) underwent priority review, 27 (57.5%) fast track, 17 (36.2%) accelerated, and 11 (23.4%) had breakthrough designation. 31 (66%) were for solid and 16 (34%) for liquid cancers. 20 (42.6%) drugs were approved based on clinical response, 16 (34.0%) on progression-free survival and 11 (23.4%) on overall survival as primary endpoints. The median time from initiation of clinical trial to approval was 42 months (range: 17 to 78 months). Trials completed within a shorter time ( < 42 months, median) were more likely to receive fast track designation compared to those requiring a longer time (36.2% vs. 21.3%; p = 0.03). We divided the 5-year study over 3 time periods from Jan 2011 - Aug 2012, Sept 2012 - April 2014, and May 2014 - Dec 2015. 13 (27.7%), 15 (31.9%), and 19 (40.4%) drugs were approved in those periods, respectively. Over time, there was a trend towards an increase in orphan-designated drugs from 14.9%, to 25.5%, to 34.0% (p = 0.13). The proportion of accelerated drugs increased from 15.4%, to 33.3%, to 52.6% over the study period, though not statistically significant (p = 0.09). There was also no change with respect to application type, phase of clinical trial, and type of trial endpoint over time. Conclusions: The majority (65%) of new cancer drugs were approved under the orphan drug designation which has increased over the past 5 years. The median time from clinical trial initiation to FDA approval was 42 months. The increasing trend for novel drug approvals through these expedited programs based on shorter and smaller clinical trials warrants further investigation.